<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646748</url>
  </required_header>
  <id_info>
    <org_study_id>39110-107</org_study_id>
    <nct_id>NCT02646748</nct_id>
  </id_info>
  <brief_title>Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors</brief_title>
  <official_title>A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or&#xD;
      metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part&#xD;
      2). Two treatment groups (Group A and Group B) will be evaluated&#xD;
&#xD;
      Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced&#xD;
      solid tumors. Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib&#xD;
      (INCB039110) in combination with pembrolizumab (MK-3475) and Group B will evaluate a&#xD;
      PI3K-delta inhibitor (INCB050465) in combination with pembrolizumab to determine the maximum&#xD;
      tolerated dose (MTD) or PAD and recommend a dose for the Part 1b safety expansion with each&#xD;
      combination.&#xD;
&#xD;
      Once the recommended dose has been identified in Part 1a, subjects with select solid tumor&#xD;
      types will be enrolled into safety expansion cohorts based upon prior treatment history with&#xD;
      a PD-1 pathway-targeted agent (Part 1b) for each combination.&#xD;
&#xD;
      Part 2 utilizes a Simon 2-Stage design to evaluate INCB050465 in combination with&#xD;
      pembrolizumab in patients with small cell lung cancer (SCLC) and a 1 stage design to evaluate&#xD;
      the combination in patients with non-small cell lung cancer (NSCLC) and urothelial cancer&#xD;
      (UC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase 1b, 3 Part (Part 1a, Part 1b, and Part 2), multi-center study.&#xD;
&#xD;
      Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced&#xD;
      solid tumors. Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib&#xD;
      (INCB039110) in combination with pembrolizumab (MK-3475) and Group B will evaluate a&#xD;
      PI3K-delta inhibitor (INCB050465) in combination with pembrolizumab to determine the maximum&#xD;
      tolerated dose (MTD) or PAD and recommend a dose for the Part 1b safety expansion with each&#xD;
      combination.&#xD;
&#xD;
      Once the recommended dose has been identified in Part 1a, subjects with endometrial cancer,&#xD;
      gastric cancer, melanoma, microsatellite unstable (MSI) colorectal cancer or other&#xD;
      MMR-deficient tumors, non-small cell lung cancer, renal cell carcinoma, head and neck&#xD;
      squamous cell carcinoma, triple negative breast cancer, pancreatic ductal carcinoma, or&#xD;
      transitional cell carcinoma of the genitourinary tract will be enrolled into safety expansion&#xD;
      cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b) for&#xD;
      each combination.&#xD;
&#xD;
      Part 2 utilizes a Simon 2-Stage design to evaluate INCB050465 in combination with&#xD;
      pembrolizumab in patients with small cell lung cancer (SCLC) and a 1 stage design to evaluate&#xD;
      the combination in patients with non-small cell lung cancer (NSCLC) and urothelial cancer&#xD;
      (UC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 25, 2016</start_date>
  <completion_date type="Anticipated">December 24, 2021</completion_date>
  <primary_completion_date type="Actual">November 7, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse events</measure>
    <time_frame>Duration of study treatment and up to 120 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Objective Response Rate (ORR) as determined by radiographic disease assessments per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) v1.1 criteria</measure>
    <time_frame>Every 9 weeks for the first year on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Change in the number of Tumor Infiltrating Lymphocytes(TILs) and the ratio of CD8+ lymphocytes to FOXP3+ cells infiltrating tumor post-treatment versus pretreatment by IHC</measure>
    <time_frame>Up to 5 weeks on study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Colorectal Cancer (CRC)</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>MMR-deficient Tumors</condition>
  <condition>Breast Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Renal Cell Carcinoma (RCC)</condition>
  <condition>Solid Tumors</condition>
  <condition>UC (Urothelial Cancer)</condition>
  <arm_group>
    <arm_group_label>pembrolizumab + itacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1a Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.&#xD;
Part 1b Group A-1 and Group A-2 will evaluate the MTD or PAD of itacitinib in combination with pembrolizumab in subjects with select solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pembrolizumab + INCB050465</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1a Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.&#xD;
Part 1b Group B-1 and Group B-2 will evaluate the MTD or PAD of INCB050465 in combination with pembrolizumab in subjects with select solid tumors.&#xD;
Part 2 will evaluate the combination of INCB050465 in combination with pembrolizumab in subjects with small cell lung cancer, non-small lung cancer and urothelial cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg IV Q3W.</description>
    <arm_group_label>pembrolizumab + INCB050465</arm_group_label>
    <arm_group_label>pembrolizumab + itacitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itacitinib</intervention_name>
    <description>Itacitinib tablets administered orally once daily.</description>
    <arm_group_label>pembrolizumab + itacitinib</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB050465</intervention_name>
    <description>INCB050465 tablets administered orally once daily.</description>
    <arm_group_label>pembrolizumab + INCB050465</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age 18 years or older.&#xD;
&#xD;
          -  Willingness to provide written informed consent for the study.&#xD;
&#xD;
          -  Has a core or excisional baseline tumor biopsy specimen available or willingness to&#xD;
             undergo a pre study treatment tumor biopsy to obtain the specimen.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          -  Presence of measureable disease based on RECIST v1.1&#xD;
&#xD;
          -  For Part 1a: Subjects with histologically or cytologically confirmed advanced or&#xD;
             metastatic solid tumors that have failed prior standard therapy (including subject&#xD;
             refusal or intolerance).&#xD;
&#xD;
          -  For Part 1b: Subjects with histologically or cytologically confirmed advanced or&#xD;
             metastatic endometrial cancer, gastric cancer, melanoma, microsatellite unstable (MSI)&#xD;
             colorectal cancer or other MMR-deficient tumors, non-small cell lung cancer, renal&#xD;
             cell carcinoma, head and neck squamous cell carcinoma, triple negative breast cancer,&#xD;
             pancreatic ductal carcinoma, or transitional cell carcinoma of the genitourinary tract&#xD;
             that have had disease progression after available therapies for advanced or metastatic&#xD;
             disease that are known to confer clinical benefit, been intolerant to treatment, or&#xD;
             refused standard treatment.&#xD;
&#xD;
          -  For Part 1b: Must have documented confirmed disease progression on a prior PD-1&#xD;
             pathway targeted agent or must be PD-1 pathway-targeted treatment na√Øve.&#xD;
&#xD;
        For Part 2&#xD;
&#xD;
        For subjects with SCLC:&#xD;
&#xD;
        Subjects with histologically or cytologically confirmed advanced or metastatic SCLC. Must&#xD;
        not have had previous treatment with antibodies that modulate T-cell function or checkpoint&#xD;
        pathways. Must have disease progression on or after platinum-based chemotherapy or must be&#xD;
        intolerant to or refuse standard treatment. Must not have received more than 2 lines of&#xD;
        prior therapy.&#xD;
&#xD;
        For subjects with NSCLC:&#xD;
&#xD;
        Subjects with a histologically or cytologically confirmed diagnosis of Stage IIIB, Stage&#xD;
        IV, or recurrent NSCLC. Have not received more than 1 prior systemic therapy for metastatic&#xD;
        NSCLC. No prior therapy with checkpoint inhibitors (anti-PD-1/PD-L1 or anti-CTLA-4). Have&#xD;
        confirmation that EGFR or ALK-directed therapy is not indicated as primary therapy&#xD;
        (documentation of absence of tumor activating EGFR mutations AND ALK gene rearrangements&#xD;
        treatable with a tyrosine kinase inhibitor (TKI) OR presence of a KRAS mutation). If&#xD;
        participant's tumor is known to have a predominantly squamous histology, molecular testing&#xD;
        for EGFR mutation and ALK translocation will not be required as this is not part of current&#xD;
        diagnostic guidelines. Have measurable disease based on RECIST 1.1.&#xD;
&#xD;
        For subjects with UC:&#xD;
&#xD;
        Subjects with a histologically or cytologically confirmed diagnosis of&#xD;
        advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis,&#xD;
        ureter, bladder, or urethra. Have had 1 prior treatment of systemic chemotherapy containing&#xD;
        a platinum agent or is considered ineligible to receive cisplatin-based combination&#xD;
        therapy. No prior therapy with checkpoint inhibitors (anti-PD-1/PD-L1 or anti-CTLA-4). Have&#xD;
        measurable disease based on RECIST 1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory parameters not within the protocol-defined range.&#xD;
&#xD;
          -  Receipt of anticancer medications or investigational drugs within a defined interval&#xD;
             before the first administration of study drug.&#xD;
&#xD;
          -  Received an immune-suppressive based treatment for any reason within 14 days prior to&#xD;
             the first dose of study treatment.&#xD;
&#xD;
          -  Has not recovered from toxic effect of prior therapy to &lt; Grade 1.&#xD;
&#xD;
          -  Active or inactive autoimmune process.&#xD;
&#xD;
          -  Has received a live vaccine within 30 days of planned start of study therapy.&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Jones, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute at Providence Saint John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center Lombardi CCC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Associates of Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>37952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Laura &amp; Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenters, Hilman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Cancer Center of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

